Biohaven Ltd.
NYSE · us_market
No AI summary generated yet for this ticker.
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity. The company is also developing BHV-1510 that is in Phase 2 clinical trial for the treatment of advanced or metastatic epithelial tumors; and BHV-1530, which is in Phase 2 clinical trial for treating urothelial cancer and other tumors. In addition, its preclinical product pipeline includes BHV-1310 for treating myasthenia gravis; BHV-1320 for treating immune mediated-diseases; BHV-1450 for treating Pemphigus, MuSK MG, and LGI-1 Encephalitis; BHV-1420 for treating membranous nephropathy; BHV-1440 for treating Graves' disease and TED; BHV-6500 for treating type 1 diabetes; BHV-1490 for treating IgM neuropathy and Waldenstrom's; BHV-8100 for treating neurodegenerative diseases; and BHV-1955 for treating tinnitus. The company was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.
Biohaven Ltd.âs R&D update: epilepsy asset, degrader programs, and 2025 catalysts incl. pivotal topline dataâplus risks from $2B+ deficit. Click for a BHVN update.
Biohaven Ltd. (NYSE: BHVN) ("Biohaven") a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies with the potential to transform autoimmune
HC Wainwright & Co. analyst Douglas Tsao reiterates Biohaven (NYSE:BHVN) with a Neutral and maintains $10 price target.
Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases,
Morgan Stanley analyst Terence Flynn maintains Biohaven (NYSE:BHVN) with a Overweight and lowers the price target from $21 to $18.
Biohaven reported first-quarter 2026 results with a net loss of US$130.53 million, narrower than a year earlier, and simultaneously filed a mixed shelf registration covering equity, debt, and other securities. Alongside improved quarterly figures, Biohaven highlighted an advancing pipeline with planned pivotal trials and key data readouts later in 2026, while bolstering its financing flexibility through the new shelf facility. With recent share price gains, we'll explore how Biohaven's...
Biohaven Ltd. (BHVN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
RBC Capital analyst Leonid Timashev maintains Biohaven (NYSE:BHVN) with a Outperform and lowers the price target from $23 to $22.
Why Biohaven’s latest earnings and financing moves matter for shareholders Biohaven (BHVN) has become a focus after reporting a narrower Q1 2026 net loss, outlining timelines for pivotal trials across its late stage pipeline, and filing a mixed shelf registration to support future funding needs. See our latest analysis for Biohaven. Those Q1 results and the mixed shelf filing arrived alongside a 5.3% 1 day share price return and a 5.7% 7 day share price return. However, this sits against a 1...
Biohaven Ltd: Biohaven Ltd files for offering of up to $350 million common shares - SEC filing...
https://www.sec.gov/Archives/edgar/data/1935979/000162828026029834/biohavens-3asr.htm
Biohaven to update clinical, regulatory, and operational progress at annual R&D Day at the upcoming Yale Innovation Summit on May 27, 2026. Advancement of high-value,...
Biohaven Ltd. (NYSE:BHVN) is one of the 10 Best Small-Cap Biotech Stocks According to Hedge Funds. The company’s stock price posted a 1.29% year-to-date increase, while it registered a 46.57% decline from a year ago. Based on an analyst consensus by TipRanks, Biohaven has an average price target of $21.44 with a moderate buy rating […]
Biohaven Ltd. (NYSE:BHVN) is one of the best low priced biotech stocks to invest in. On April 13, Canaccord initiated coverage of Biohaven Ltd. (NYSE:BHVN) with a Buy rating and set a $21 price target on the stock. The firm told investors in a research note that the company is in the process of developing novel […]
Biohaven Ltd. downgraded after FDA CRL for troriluzole; see its pipeline shift to obesity/neurology, Phase 2 catalysts, and cash runway. Click for this BHVN update.
The biotech was boosted by an analyst's initiation of coverage.
Biohaven Ltd. (NYSE:BHVN) is one of the 8 Healthcare Stocks Insiders Are Buying. On April 2, 2026, Citi analyst Samantha Semenkow raised the price target on Biohaven Ltd. (NYSE:BHVN) to $17 from $14 and maintained a Buy rating. Samantha Semenkow said the firm sees attractive risk/reward at current levels ahead of 2026 catalysts, noting recent […]
Citigroup analyst Samantha Semenkow maintains Biohaven (NYSE:BHVN) with a Buy and raises the price target from $14 to $17.
Biohaven Ltd. (NYSE:BHVN) is one of the 7 best small-cap healthcare stocks to buy according to hedge funds. On March 11, Ken Cacciatore from TD Cowen increased the price target on Biohaven Ltd. (NYSE:BHVN) from $15 to $30. The analyst maintained a Buy rating on the stock, which yields an adjusted upside potential of more […]
In March 2026, Biohaven announced it had completed enrollment in a 150-patient Phase 2 proof‑of‑concept trial of taldefgrobep alfa, a myostatin‑activin pathway inhibitor being tested as a self‑administered obesity treatment with both weekly and monthly dosing arms. The program is drawing interest because prior human and animal data suggest this pathway could influence both fat and lean mass, potentially differentiating taldefgrobep from existing obesity therapies that are often associated...
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| StateStreet | passive | 6.62M | $56.00M | 0.00% | Added+15.8% | 2026-03-31 |
| DEShaw | quant | 2.85M | $24.09M | 0.01% | Added+5.7% | 2026-03-31 |
| FidelityFMR | fundamental | 2.36M | $19.96M | 0.00% | Trimmed-12.0% | 2026-03-31 |
| CapResearch | fundamental | 1.33M | $11.28M | 0.00% | Unchanged | 2026-03-31 |
| TwoSigma | quant | 1.19M | $10.04M | 0.01% | Trimmed-5.7% | 2026-03-31 |
| Citadel | multi-strat | 373.1K | $3.16M | 0.00% | Trimmed-3.8% | 2026-03-31 |
| RenTech | quant | 161.0K | $1.36M | 0.00% | New | 2026-03-31 |
| TRowePrice | fundamental | 2.22M | $18.76K | 0.00% | Added+9.8% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-10upcoming | -0.61 | — | — |
| 2026-05-04 | -0.76 | -0.69 | +9.68% |
| 2026-03-02 | -0.96 | -0.90 | +5.77% |
| 2025-11-10 | -1.54 | -1.47 | +4.81% |
| 2025-08-11 | -1.57 | -1.63 | -3.96% |
| 2025-05-12 | -1.47 | -1.64 | -11.24% |
| 2025-03-03 | -1.47 | -1.71 | -16.23% |
| 2024-11-12 | -1.55 | -1.74 | -12.21% |
| 2024-08-08 | -1.70 | -3.50 | -106.15% |
| 2024-05-09 | -1.62 | -1.77 | -9.37% |
| 2024-02-29 | -1.34 | -1.61 | -19.86% |
| 2023-11-14 | -1.34 | -1.50 | -11.59% |
| 2023-07-31 | -1.19 | -1.32 | -10.51% |
| 2023-05-12 | -1.41 | -1.03 | +26.96% |
| 2023-03-23 | -1.28 | -3.32 | -159.93% |
| 2022-11-09 | -2.41 | -1.75 | +27.54% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| BHVN | +14.33% | +3.19% | -2.48% | -25.66% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | +11.36% | +7.82% | +0.96% | -38.35% |